Recently, Dr. Pierre Kory appeared before a Senate Committee on Homeland Security and Governmental Affairs to discuss his team’s use of Ivermectin in treating and preventing COVID-19. Dr. Kory testified that he believes COVID-19 patients should be treated much earlier than the current CDC guidelines recommend. Kory provided an information packet that contained documentation on his team’s use of Ivermectin in treating COVID patients, along with studies of Ivermectin’s successful use world wide, in all disease phases and begged the USG agencies responsible to review the information and issue guidelines for Ivermectin’s early use in treating COVID-19.
It seems India had already discovered Ivermectin’s efficacy in treating the SAR COv2 virus back in August of this year. In the Indian Express on 8 August the following headline appeared: “New Protocol Ivermectin to replace HCQ (Hydroxychloroquine) in treatment of Covid patients.” The newspaper noted that sources in the government said that the decision to replace Hydroxychloroquine (HCQ) with Ivermectin was taken after encouraging results in Agra, where it was used on an experimental basis.
Now, the treatment protocol specified by Dr. Kory and his team is being manufactured in India under the brand name “Ziverdo Kit” and costs approximately $2.65 per person. The Indian version of the protocol substitutes a less expensive anti-biotic than in Dr. Kory’s protocol.
As noted in an earlier article in AND, Ivermectin has been around for over fifty years and is considered a very safe drug. Dr. Kory and his team also recommend that individuals at high risk of not dealing well with COVID-19 consider taking Ivermectin prophylactically as well – after an initial two day dosing, the drug is then taken monthly.